Coadministration of sofosbuvir/velpatasvir (400/100 mg, once daily) and rilpivirine (25 mg once daily, with emtricitabine and tenofovir-DF) was studied in 24 healthy volunteers in a cross-over study. Sofosbuvir AUC and Cmax increased by 16% and 9%; AUC and Cmin of GS-331007 increased by 4% and 12%, but Cmax decreased by 4%. Velpatasvir AUC and Cmax decreased by 1% and 4% but Cmin increased by 2%. Rilpivirine AUC, Cmax and Cmin decreased by 5%, 7% and 4%, respectively. Sofosbuvir/velpatasvir and rilpivirine-containing regimens may be coadministered without dose adjustment.